Sural nerve sensory response in diabetic distal symmetrical polyneuropathy

Yun Ru Lai; Chih Cheng Huang; Wen Chan Chiu; Rue Tsuan Liu; Nai Wen Tsai; Hung Chen Wang; Wei Che Lin; Ben Chung Cheng; Yu Jih Su; Chih Min Su; Sheng Yuan Hsiao; Hsueh Wen Chang; Jung Fu Chen; Jih Yang Ko; Cheng Hsien Lu

doi:10.1002/mus.26739

Sural nerve sensory response in diabetic distal symmetrical polyneuropathy

Yun Ru Lai
, Chih Cheng Huang
, Wen Chan Chiu
, Rue Tsuan Liu
, Nai Wen Tsai
, Hung Chen Wang
, Wei Che Lin
, Ben Chung Cheng
, Yu Jih Su
, Chih Min Su
, Sheng Yuan Hsiao
, Hsueh Wen Chang
, Jung Fu Chen
, Jih Yang Ko
, Cheng Hsien Lu^*

^*Corresponding author for this work

National Sun Yat-sen University
Penghu Hospital
Chang Gung University
Xiamen Chang Gung Hospital

Research output: Contribution to journal › Journal Article › peer-review

13 Scopus citations

Abstract

Introduction: The sural sensory nerve action potential (SNAP) amplitude is a measure of the number of axons. We tested the hypothesis that sural SNAP amplitude can be used as a marker in screening, severity evaluation, and follow-up of diabetic distal symmetrical polyneuropathy (DSPN). Methods: Patients with type 2 diabetes underwent nerve conduction studies and were followed for 6 years. Composite amplitude scores (CASs) were determined to evaluate DSPN severity. Results: Sural SNAP amplitudes were negatively correlated with CAS (r = −.790, P <.0001), and changes in sural SNAP amplitudes were negatively correlated with those of CAS after controlling for follow-up duration (r = −.531, P =.028). Discussion: When a patient's baseline sural SNAP amplitude is above zero, it can be used as one measure of DSPN in screening, severity evaluation, and follow-up. However, if the patient's sural SNAP value is zero, CAS can be used as a follow-up measure.

Original language	English
Pages (from-to)	88-94
Number of pages	7
Journal	Muscle and Nerve
Volume	61
Issue number	1
DOIs	https://doi.org/10.1002/mus.26739
State	Published - 01 01 2020

Bibliographical note

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

composite amplitudes score
diabetic distal symmetrical polyneuropathy
follow-up
screening
severity evaluation
sural sensory nerve action potential
type 2 diabetes

Access to Document

10.1002/mus.26739

Cite this

@article{d9f4f83602fe45bd8cc04c89aa85aa7a,

title = "Sural nerve sensory response in diabetic distal symmetrical polyneuropathy",

abstract = "Introduction: The sural sensory nerve action potential (SNAP) amplitude is a measure of the number of axons. We tested the hypothesis that sural SNAP amplitude can be used as a marker in screening, severity evaluation, and follow-up of diabetic distal symmetrical polyneuropathy (DSPN). Methods: Patients with type 2 diabetes underwent nerve conduction studies and were followed for 6 years. Composite amplitude scores (CASs) were determined to evaluate DSPN severity. Results: Sural SNAP amplitudes were negatively correlated with CAS (r = −.790, P <.0001), and changes in sural SNAP amplitudes were negatively correlated with those of CAS after controlling for follow-up duration (r = −.531, P =.028). Discussion: When a patient's baseline sural SNAP amplitude is above zero, it can be used as one measure of DSPN in screening, severity evaluation, and follow-up. However, if the patient's sural SNAP value is zero, CAS can be used as a follow-up measure.",

keywords = "composite amplitudes score, diabetic distal symmetrical polyneuropathy, follow-up, screening, severity evaluation, sural sensory nerve action potential, type 2 diabetes",

author = "Lai, \{Yun Ru\} and Huang, \{Chih Cheng\} and Chiu, \{Wen Chan\} and Liu, \{Rue Tsuan\} and Tsai, \{Nai Wen\} and Wang, \{Hung Chen\} and Lin, \{Wei Che\} and Cheng, \{Ben Chung\} and Su, \{Yu Jih\} and Su, \{Chih Min\} and Hsiao, \{Sheng Yuan\} and Chang, \{Hsueh Wen\} and Chen, \{Jung Fu\} and Ko, \{Jih Yang\} and Lu, \{Cheng Hsien\}",

note = "Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",

year = "2020",

month = jan,

day = "1",

doi = "10.1002/mus.26739",

language = "英语",

volume = "61",

pages = "88--94",

journal = "Muscle and Nerve",

issn = "0148-639X",

publisher = "John Wiley \& Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Sural nerve sensory response in diabetic distal symmetrical polyneuropathy

AU - Lai, Yun Ru

AU - Huang, Chih Cheng

AU - Chiu, Wen Chan

AU - Liu, Rue Tsuan

AU - Tsai, Nai Wen

AU - Wang, Hung Chen

AU - Lin, Wei Che

AU - Cheng, Ben Chung

AU - Su, Yu Jih

AU - Su, Chih Min

AU - Hsiao, Sheng Yuan

AU - Chang, Hsueh Wen

AU - Chen, Jung Fu

AU - Ko, Jih Yang

AU - Lu, Cheng Hsien

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Introduction: The sural sensory nerve action potential (SNAP) amplitude is a measure of the number of axons. We tested the hypothesis that sural SNAP amplitude can be used as a marker in screening, severity evaluation, and follow-up of diabetic distal symmetrical polyneuropathy (DSPN). Methods: Patients with type 2 diabetes underwent nerve conduction studies and were followed for 6 years. Composite amplitude scores (CASs) were determined to evaluate DSPN severity. Results: Sural SNAP amplitudes were negatively correlated with CAS (r = −.790, P <.0001), and changes in sural SNAP amplitudes were negatively correlated with those of CAS after controlling for follow-up duration (r = −.531, P =.028). Discussion: When a patient's baseline sural SNAP amplitude is above zero, it can be used as one measure of DSPN in screening, severity evaluation, and follow-up. However, if the patient's sural SNAP value is zero, CAS can be used as a follow-up measure.

AB - Introduction: The sural sensory nerve action potential (SNAP) amplitude is a measure of the number of axons. We tested the hypothesis that sural SNAP amplitude can be used as a marker in screening, severity evaluation, and follow-up of diabetic distal symmetrical polyneuropathy (DSPN). Methods: Patients with type 2 diabetes underwent nerve conduction studies and were followed for 6 years. Composite amplitude scores (CASs) were determined to evaluate DSPN severity. Results: Sural SNAP amplitudes were negatively correlated with CAS (r = −.790, P <.0001), and changes in sural SNAP amplitudes were negatively correlated with those of CAS after controlling for follow-up duration (r = −.531, P =.028). Discussion: When a patient's baseline sural SNAP amplitude is above zero, it can be used as one measure of DSPN in screening, severity evaluation, and follow-up. However, if the patient's sural SNAP value is zero, CAS can be used as a follow-up measure.

KW - composite amplitudes score

KW - diabetic distal symmetrical polyneuropathy

KW - follow-up

KW - screening

KW - severity evaluation

KW - sural sensory nerve action potential

KW - type 2 diabetes

UR - https://www.scopus.com/pages/publications/85074751411

U2 - 10.1002/mus.26739

DO - 10.1002/mus.26739

M3 - 文章

C2 - 31614013

AN - SCOPUS:85074751411

SN - 0148-639X

VL - 61

SP - 88

EP - 94

JO - Muscle and Nerve

JF - Muscle and Nerve

IS - 1

ER -

Sural nerve sensory response in diabetic distal symmetrical polyneuropathy

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this